ERBB2 and gastric cancer: Human epidermal growth factor receptor‐2 (HER2) was overexpressed in 9.0%–38% of patients with advanced gastric cancer (AGC) who would benefit from trastuzumab, a humanized monoclonal antibody that targets targeted HER2.4, 5, 6, 7, 8